Literature DB >> 28154291

Improvement in Quality of Life and Hemodynamics in Chronic Thromboembolic Pulmonary Hypertension Treated With Balloon Pulmonary Angioplasty.

Szymon Darocha1, Radosław Pietura, Arkadiusz Pietrasik, Justyna Norwa, Anna Dobosiewicz, Michał Piłka, Michał Florczyk, Andrzej Biederman, Adam Torbicki, Marcin Kurzyna.   

Abstract

BACKGROUND: The effect of balloon pulmonary angioplasty (BPA) on improvement in functional and hemodynamic parameters in chronic thromboembolic pulmonary hypertension (CTEPH) is known, but the quality of life (QoL) of patients treated with BPA has never been studied before.Methods and 
Results: Twenty-five patients with inoperable or persistent CTEPH were enrolled in the study and filled out the 36-item Short Form (SF-36v2) questionnaire twice: prior to commencement of BPA treatment and after ≥3 BPA sessions. In addition WHO functional class, distance on the 6-min walk test (6MWT) and hemodynamic parameters such as right atrial pressure (RAP), mean pulmonary artery pressure (mPAP), cardiac index (CI) and pulmonary vascular resistance (PVR) were assessed. QoL improved significantly in all domains, except for physical pain. Improvement in RAP (10.5±3.4 vs. 6.2±2.2 mmHg; P<0.05), mPAP (51.7±10.6 vs. 35.0±9.1 mmHg; P<0.05), CI (2.2±0.5 vs. 2.5±0.4 L/min·m2; P=0.04), PVR (10.4±3.9 vs. 5.5±2.2 Wood units; P<0.05), functional class (96% vs. 20% in WHO class III and IV, P<0.05) and improvement in 6MWT distance (323±135 vs. 410±109 m; P<0.05) was observed. The only significant correlation was between the mental component summary score of QoL after completion of treatment and percentage improvement in the 6MWT (-0.404, P<0.05).
CONCLUSIONS: Alongside improvement in functional and hemodynamic parameters, BPA also provides significant improvement in QoL.

Entities:  

Mesh:

Year:  2017        PMID: 28154291     DOI: 10.1253/circj.CJ-16-1075

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  11 in total

1.  Meta-analysis of use of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension.

Authors:  Muhammad Shahzeb Khan; Emaan Amin; Muhammad Mustafa Memon; Naser Yamani; Tariq Jamal Siddiqi; Safi U Khan; Mohammad Hassan Murad; Farouk Mookadam; Vincent M Figueredo; Rami Doukky; Raymond L Benza; Richard A Krasuski
Journal:  Int J Cardiol       Date:  2019-02-23       Impact factor: 4.164

Review 2.  Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.

Authors:  Amanda Lloji; Urvashi Hooda; Jayakumar Sreenivasan; Ramin Malekan; Wilbert S Aronow; Gregg M Lanier
Journal:  Am J Cardiovasc Dis       Date:  2021-06-15

3.  Augmented reality and three-dimensional printing in percutaneous interventions on pulmonary arteries.

Authors:  Jan Witowski; Szymon Darocha; Łukasz Kownacki; Arkadiusz Pietrasik; Radosław Pietura; Marta Banaszkiewicz; Jakub Kamiński; Andrzej Biederman; Adam Torbicki; Marcin Kurzyna
Journal:  Quant Imaging Med Surg       Date:  2019-01

Review 4.  Advances in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.

Authors:  Ehtisham Mahmud; Mitul Patel; Lawrence Ang; David Poch
Journal:  Pulm Circ       Date:  2021-05-24       Impact factor: 3.017

5.  Impact of Balloon Pulmonary Angioplasty on Hemodynamics and Clinical Outcomes in Patients with Chronic Thromboembolic Pulmonary Hypertension: the Initial Korean Experience.

Authors:  Woochan Kwon; Jeong Hoon Yang; Taek Kyu Park; Sung A Chang; Dong Seop Jung; Young Seok Cho; Sung Mok Kim; Tae Jung Kim; Hye Yoon Park; Seung Hyuk Choi; Duk Kyung Kim
Journal:  J Korean Med Sci       Date:  2018-01-22       Impact factor: 2.153

6.  Medium-term health-related quality of life in patients with pulmonary arterial hypertension treated with goal-oriented sequential combination therapy based on exercise capacity.

Authors:  Akihiro Hirashiki; Shiro Adachi; Naoki Okumura; Yoshihisa Nakano; Shigetake Shimokata; Atsuya Shimizu; Hidenori Arai; Kenji Toba; Toyoaki Murohara; Takahisa Kondo
Journal:  Health Qual Life Outcomes       Date:  2019-06-14       Impact factor: 3.186

7.  Treatment of chronic thromboembolic pulmonary hypertension in a multidisciplinary team.

Authors:  Anna Siennicka; Szymon Darocha; Marta Banaszkiewicz; Piotr Kędzierski; Anna Dobosiewicz; Piotr Błaszczak; Małgorzata Peregud-Pogorzelska; Jarosław Damian Kasprzak; Michał Tomaszewski; Ewa Mroczek; Bożena Zięba; Danuta Karasek; Katarzyna Ptaszyńska-Kopczyńska; Katarzyna Mizia-Stec; Tatiana Mularek-Kubzdela; Anna Doboszyńska; Ewa Lewicka; Marcin Ruchała; Maciej Lewandowski; Sylwia Łukasik; Łukasz Chrzanowski; Dariusz Zieliński; Adam Torbicki; Marcin Kurzyna
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

8.  Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty.

Authors:  Marta Banaszkiewicz; Arkadiusz Pietrasik; Michał Florczyk; Piotr Kędzierski; Michał Piłka; Rafał Mańczak; Janusz Kochman; Grzegorz Opolski; Adam Torbicki; Marcin Kurzyna; Szymon Darocha
Journal:  Diagnostics (Basel)       Date:  2021-01-16

9.  Effect of Living Environment Factors on Quality of Life in Patients With Chronic Thromboembolic Pulmonary Hypertension After Completion of Balloon Pulmonary Angioplasty - A Cross-Sectional Study.

Authors:  Yosuke Morimoto; Satoshi Ikeda; Yuki Yamagata; Ryo Kozu; Hiroaki Kawano; Koji Maemura
Journal:  Circ Rep       Date:  2021-04-03

10.  Assessment of electrocardiographic markers of acute and long-term hemodynamic improvement in patients with pulmonary hypertension.

Authors:  Michał Piłka; Szymon Darocha; Marta Banaszkiewicz; Maria Wieteska-Miłek; Małgorzata Mańczak; Rafał Mańczak; Piotr Kędzierski; Michał Florczyk; Anna Dobosiewicz; Adam Torbicki; Marcin Kurzyna
Journal:  Ann Noninvasive Electrocardiol       Date:  2020-04-26       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.